Reviewed by a GPhC-registered Pharmacist at Newdays Pharmacy | Published: 2026 | Book an appointment
| Quick Answer: Most people regain a significant proportion of the weight they lost on Mounjaro or Wegovy within one to two years of stopping the medication. Clinical trials show that weight regain is driven by the return of the biological drivers of obesity including elevated appetite hormones. Stopping treatment is a clinical decision that should always be discussed with your prescriber, not made independently. Long term treatment planning is an important part of any weight management programme. |
One of the most clinically important conversations in weight management consultations at Newdays Pharmacy in Berkshire is what happens when patients consider stopping their GLP-1 and GIP/GLP-1 medication. The honest clinical answer is not what many patients want to hear, but understanding it is essential for making informed, realistic decisions about weight management treatment.
What the Clinical Trial Data Shows About Stopping GLP-1 Medication
The STEP 4 trial (for semaglutide, the active ingredient in Wegovy) directly addressed what happens after stopping treatment. Participants who had achieved significant weight loss on semaglutide 2.4 mg over sixty eight weeks were randomised to continue on semaglutide or switch to placebo for a further forty eight weeks. Those who switched to placebo regained on average two thirds of the weight they had previously lost within fifty two weeks. Importantly, their cardiometabolic health markers, blood pressure, blood glucose, and lipid profiles, also deteriorated toward pre-treatment baseline levels.
Similar findings were observed in the SURMOUNT-4 withdrawal trial for tirzepatide (Mounjaro). Participants who stopped tirzepatide after achieving significant weight loss regained substantially more weight than those who continued treatment.
Why Weight Returns: The Biology of Obesity
Weight regain after stopping GLP-1 and GIP/GLP-1 therapy is not a failure of willpower. It is the predictable consequence of removing a pharmacological intervention that was correcting an underlying biological dysregulation. Obesity involves dysregulated appetite hormones, elevated ghrelin (the hunger hormone), reduced leptin sensitivity, and a resetting of the body’s defended weight point at a higher level. When GLP-1 and GIP/GLP-1 medication is stopped, these underlying drivers return, hunger increases, satiety decreases, and body weight trends back toward its pre-treatment level.
So Should I Stay on Medication Indefinitely?
This is a question for your prescriber, and the answer depends on your individual clinical situation, your weight, your health risk profile, your tolerance of the medication, and the cost implications for you. Many clinical guidelines frame obesity as a chronic disease requiring long term management, analogous to hypertension requiring long term antihypertensive therapy. Just as it would be unusual to stop a blood pressure medicine and expect blood pressure to remain controlled, it is similarly unusual to expect maintained weight loss after stopping a medicine that was actively required to achieve it.
That said, a meaningful minority of patients who make significant, sustained lifestyle changes during their treatment period may maintain more of their weight loss after stopping medication than the average seen in withdrawal trials. The structured lifestyle support element of a properly managed weight loss programme is specifically designed to maximise this possibility.
| Book Now: Book a Travel Health Consultation or Weight Management Appointment: We serve patients from Windsor, Eton, Twyford, Reading, and across Berkshire and Buckinghamshire. |
Frequently Asked Questions
Clinical trial data suggest that weight regain can begin within the first few months after stopping Mounjaro (tirzepatide). In the SURMOUNT-4 study, many participants regained a significant proportion of their lost weight over the following year. The amount and speed of weight regain vary depending on individual biology, lifestyle and long-term weight management strategies.
Yes. GLP-1 and dual GIP/GLP-1 medicines do not require gradual dose reduction for safety and can usually be stopped without tapering. However, stopping treatment should always be discussed with your prescriber so that a plan is in place to help maintain your weight after treatment ends.
Yes. Many people can restart Mounjaro or Wegovy after a new clinical assessment. In most cases, treatment begins again at the starting dose before gradually increasing according to the recommended titration schedule to minimise gastrointestinal side effects.
| Clinical Disclaimer: This article is intended for general information only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment or medication. Information is accurate as of the date of publication and reviewed by a GPhC-registered pharmacist. Newdays Pharmacy is registered with the General Pharmaceutical Council (GPhC). Branch registration numbers: Eton/Windsor 1029048 | Twyford 1028983 | Coley Park Reading 1029008. |